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treatment.
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INTRODUCTION
Malignant pleural mesothelioma (MPM) is a rare,
aggressive, and devastating disease of the
thoracic cavity associated with asbestos expo-
sure. In recent years, MPM incidence has been ris-
ing and, although the use of asbestos has been
prohibited in 55 countries, it is not expected to
decrease until 2030.1,2 A report from the Interna-
tional Agency for Research on Cancer indicates
that the disease burden is still substantial, with
30,443 cases of malignant mesothelioma and
25,576 deaths worldwide according to GLOBO-
CAN 2018 statistics.3,4 The treatment options are
restricted by the poor prognosis and short life ex-
pectancy of 8 to 15 months5 from diagnosis. Sur-
gery is part of the most effective multimodality
treatment in prolonging survival and is a possible
option for patients with a good prognosis in high-
volume experienced centers.3
Selection criteria for surgery and identification of
the appropriate candidate are crucial, and it is
strongly recommended that a maximal surgical
cytoreduction should be performed.6 Maximal
surgical cytoreduction as a single-modality treat-
ment is generally insufficient; additional antineo-
plastic treatment (chemotherapy and/or radiation
therapy) should be administered.6 It is recommen-
ded that any treatment decision should be made
with multidisciplinary input involving thoracic sur-
geons, pulmonologists, medical and radiation on-
cologists, radiologists, and pathologists to find
the best therapeutic options for each individual
patient.6
To provide recommendation for identification of
benefit from surgery, many factors have to be
taken into account: selection of candidates for sur-
gery by clinical predicators and pathology with
summary of the different predictor scores, as
well as availability and access to different treat-
ment approaches. This article summarizes these
prognostic factors.
CLINICAL AND RADIOLOGIC PREOPERATIVE
PROGNOSTIC FACTORS
Research focused on identification of clinical se-
lection criteria for surgery in a multimodality
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KEY POINTS
 Patients with malignant pleural mesothelioma have a poor prognosis.
 In current guidelines, surgery is the recommended option in selected patients with early-stage dis-
ease as part of a multimodal approach.
 Preoperative identification of factors associated with improved outcome is crucial for decision-
making.
 The available literature for prognostic factors and scores for treatment allocation for surgery are
presented.
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therapy approach was initiated in 1976, when
Butchart and colleagues7 in Newcastle (UK)
described the importance of precise patient selec-
tion for surgery. Butchart was one of the pioneers
in mesothelioma surgery and concluded that
death could have been prevented by better case
selection, alteration in surgical technique, and bet-
ter postoperative management.7
The unpredictable biological behavior of meso-
thelioma, the lack of correlation between clinical
and pathologic staging, and patients’ individual
risk factors make the best treatment allocation
difficult for an individual patient.
In general, specific considerations such as clin-
ical factors (patients’ demographics, performance
status, specific prognostic markers in blood8–13
and pleural effusion,14 serologic markers of inflam-
mation15 and activated immune response,16,17
cardiac18 and pulmonary assessments,19 radio-
logic staging, and tumor response to neoadjuvant
chemotherapy) and pathologic factors (histology,
genetic background, and molecular biomarkers),
together with prognostic scores to select the pa-
tients for curative MPM surgery, are discussed in
this article.
Historically, Butchart and colleagues7 divided
their cohort of 29 patients in 1976 into “fit” and
“unfit” for surgery and categorized them addition-
ally into “above 60 years” or “below 60 years” of
age. In general, age and, in early publications,
white race were predictors for cancer-directed
surgery,20 and advanced age was frequently
mentioned as a significant factor associated with
poor survival in previous reports.21–24 With chang-
ing demographics, age is currently a less stringent
exclusion criterion for surgery; however, in the
literature the age limit for favorable outcome varies
from younger than 45 years25 to younger than
70 years6 (overall survival [OS] 19.8 vs
11.7 months; P<.001, multivariate analysis)26 as
an independent prognostic factor, and surgery
was associated with improved survival in patients
aged70 years but not in those aged80 years in
a Cox proportional hazards survival model pub-
lished by Yang and colleagues.23 Consistent with
these results, the Beijing group of Zhuo and col-
leagues27 used the recent SEER (Surveillance,
Epidemiology, and End Results) database to pro-
duce a nomogram showing that the mortality risk
increases strongly with increasing age in patients
older than 70 years. Thus, surgery on patients
older than 70 years must be very carefully decided
upon because it may not translate into a survival
benefit.27 Another prognosticator of outcome and
survival after surgery for MPM is gender. Female
gender was associated with improved survival21,28
(OS 12.0 vs 9.9 months, P<.001;29 and 22 [95%
confidence interval (CI)] 18–30] vs 14 months
[95% CI 13–16]25). Male gender (hazard ratio
[HR] 1.486, 95% CI 1.241–1.7725) was indepen-
dently associated with reduced OS (all P< .05).27
Circulating estrogen, present in young but not
older women, and the expression of the estrogen
receptor b, have been suggested to play a role in
the survival difference between genders.30,31 In
one of the first studies by Curran and colleagues10
the combination of poor performance status
Eastern Cooperative Oncology Group (ECOG) sta-
tus 1 or 2, high white blood cell (WBC) count
(>8.3  109/L), and male gender were in general
associated with poor prognosis,32,33 whereas
ECOG status 0 (27.4 vs 9.7 months; P 5 .015)
was a preoperative factor predicting benefit for
surgery and survival.29 Analyses of large datasets
defined negative prognostic factors such as poor
performance status (PS), low hemoglobin (Hb)
count, male gender, high platelet count, high
lactate dehydrogenase (LDH) level, and high
WBC count.12 Neutrophil-to-lymphocyte ratio
(NLR) less than 5 (11.9 vs 7.5 months; P<.001),
platelet count less than 400 G/L (11.5 vs
7.2 months; P<.001) and normal Hb (16.4 vs
8.8 months; P<.001) are factors predicting benefit
for MPM surgery and long-term survival.29,34
C-reactive protein (CRP) is a typical
inflammation-related independent prognostic
biomarker (HR 2.07, 95% CI 1.23–3.46; P 5 .01),
and patients with increased levels in blood had
shorter OS in comparison with normal CRP (CRP
 1 mg/dL: HR 2.81, 95% CI 1.82–4.33;
P<.001).16 Furthermore, increased CRP in pleural
effusion35 was associated with worse outcome
(CRP  3.8 mg/dL: HR 2.288, CI 1.505–3.478;
P< .001).36
Other hematologic markers associated with
diagnosis and prognosis (discussed in detail in
Harvey I. Pass and colleagues’ article,
“Mesothelioma Biomarkers: Discovery in Search
of Validation,” in this issue) include soluble
mesothelin-related proteins, osteopontin, Fibulin-
3, high-mobility group box 1 (HMGB1),
lymphocyte-to-monocyte ratio (LMR), NLR, and
platelet-to-lymphocyte ratio (PLR).37,38 HMGB1,
a damage-associated molecular pattern protein
released by necrotic cells, has diagnostic and
prognostic value,39,40 with an inverse association
between HMGB1 serum levels and survival at a
cutoff value of 9 ng/mL. Lastly, the most promising
hematologic marker is the peripheral blood marker
LMR, given its proven correlation with survival.
Yamagishi and colleagues41 showed that patients
with LMR serum level greater than 2.74 had longer
OS of 14 months in comparison with 5 months at a
lower level.
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Current guidelines of the British Thoracic Soci-
ety (BTS) recommend the use of specific factors
to determine prognosis at baseline and timing of
treatment.42 These comprise demographic factors
(age, gender, race), disease features (histologic
subtype and grade, site of disease, disease stage
using various staging systems), ECOG PS or Kar-
nofski performance score, symptoms (chest pain,
weight loss), total WBC count, platelet count,
NLR, PLR, CRP level, and blood test markers
such as Hb level, Hb difference from a population
ideal value (160 g/L in men, 140 g/L in women),
and serum albumin (all grade D).42
Concerning the application of the of the non–tis-
sue-based biomarkers for diagnosis, predicting
outcome, or monitoring tumor response, the cur-
rent American Society of Clinical Oncology
(ASCO) guidelines state that these markers are un-
der evaluation and at this time do not have the
sensitivity or specificity to predict outcome or
monitor tumor response, and are therefore not rec-
ommended (Type of recommendation: evidence
based; Evidence quality: intermediate; Strength
of recommendation: moderate).6
The selection process based on radiologic fea-
tures to decide which patients are eligible for sur-
gery is challenging and requires expertise and
interdisciplinary collaboration. According to cur-
rent ASCO guidelines, patients with transdiaph-
ragmatic disease and multifocal chest wall
invasion (ie, all features that exclude patients
from macroscopic complete resection [MCR])
should undergo neoadjuvant treatment before
consideration of maximal surgical cytoreduction.6
These staging questions should be addressed by
the following investigations: computed tomogra-
phy (CT) scan with intravenous (IV) contrast (chest
and upper abdomen) and [18F]fluorodeoxyflucose
PET/CT (18F-FDG PET/CT) scan (Type of recom-
mendation: evidence based; Evidence quality: in-
termediate; Strength of recommendation: strong)
or MRI, particularly with IV contrast (Type of
recommendation: evidence based; Evidence qual-
ity: intermediate; Strength of recommendation:
moderate), as recommended by ASCO
guidelines.6
In accordance with BTS guidelines, concerning
imaging modalities for diagnosing and staging,
CT scan of thorax with IV contrast is recommen-
ded for the initial imaging modality as well as
PET/CT to exclude distant metastases—but not
for aiding diagnosis in patients who have had prior
talc pleurodesis and with caution in populations
with a high prevalence of tuberculosis—in addition
to MRI for patients in whom differentiating T stage
will change management (all grade D).42 In gen-
eral, the radiologic staging often has a poor
correlation with pathologic staging.43 Additional
radiologic assessments with functional imaging
techniques using MRI, such as diffusion-
weighted imaging (DWI) and dynamic contrast-
enhanced (DCE) MRI with 18F-FDG PET/CT, can
rule out chest wall infiltration, transdiaphragmatic
infiltration, nodal involvement, or occult metastasis
at the same time.44,45
Although staging algorithms for MPM are dis-
cussed in detail in R. Taylor Ripley’s article,
“Extended Pleurectomy and Decortication for
Malignant Pleural Mesothelioma,” in this issue, a
word about exclusion of patients from surgery
based on clinical stage is timely. Overall, the deci-
sion to undergo surgery should still be made on an
individual basis.
Traditionally, TNM stage is the classic prognos-
ticator for cancer treatment. Both parameters—T
stage and N stage—combined with epithelial his-
tology, female gender, and adjuvant therapy are
the traditionally identified prognostic factors in pa-
tients with MPM46; however, nowadays the
discrimination between T2 and T3 (infiltration of
chest wall) is almost impossible. Moreover, there
are no precise selection criteria based on T factors
alone.47–49 The current American Joint Committee
on Cancer/Union for International Cancer Control
classification50 mentions difficulties in applying it
to clinical staging with respect to both T and N pa-
rameters, resulting in imprecise predicted prog-
nosis; moreover, as strongly recommended in
ASCO guidelines, clinicians should recognize
that in patients with clinical stage I/II disease,
upstaging may occur at surgery.6 In the last pro-
posals for revision of the T descriptors, survival
correlated with pleural thickness. Pleural thickness
showed an increase at higher T stages and was
significantly associated with node positivity and
overall stage. Based on these findings and data
from the seventh edition of T categories and over-
all stage, survival showed amedian of 23.4 months
for the lowest tumor thickness (<16.0 mm) vs
13.2 months for the highest tumor thickness
(>50.0 mm).51 Nevertheless, further investigations
as to whether tumor thickness should be included
in future staging systems are necessary. Tumor
stages I to III are included if deemed technically
resectable, with most of the patients treated within
clinical trial protocols. Decisions leading to surgery
are made individually, and even localized chest
wall infiltration is accepted if chest wall resection
seems feasible and reasonable at only one level.
In this regard, another important prognosticator
is the status of mediastinal lymph node involve-
ment (N factor), which is a poor prognostic factor
for MPM as mentioned in several studies 2 de-
cades ago.46,52,53 Mediastinal staging is
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performed with PET/CT, EBUS/FNA (endobrachial
ultrasound elastography/fine-needle aspiration),
or mediastinoscopy to exclude N3 disease.54 Pa-
tients with histologically confirmed contralateral
mediastinal or supraclavicular lymph node involve-
ment should undergo neoadjuvant treatment
before consideration of maximal surgical cytore-
duction according to recent ASCO guidelines.6
The proposal for current eighth edition of the Inter-
national Association for the Study of Lung Cancer
Mesothelioma Staging Project showed that for
clinically staged tumors there was no difference
between cN0, cN1, or cN2 (cN1 vs cN0: HR
1.06, P 5 .77 and cN2 vs cN1: HR 1.04,
P 5 .85), and patients with pN1 or pN2 tumors
had shorter survival than those with pN0 tumors
(HR 1.51, P<.0001), but no survival difference
was observed between those with pN1 and pN2
tumors (HR 0.99, P 5 .99). Patients with concur-
rent pN1/pN2 nodal involvement had poorer sur-
vival than those with pN2 tumors alone (HR 1.60,
P 5 .007) or pN0 tumors (HR 1.62, P<.0001).55
Occult nodal disease detected during resection
for cN0 MPM correlate with higher hazard of mor-
tality (P 5 .005)56 and poorer prognosis with
similar survival as cN1 cases. These data under-
line the importance of routine preoperative patho-
logic nodal assessment for potentially resectable
MPM and that the number of involved lymph
nodes (rather than current location-based classifi-
cation) is associated with OS and may provide
more robust prognostic stratification for future
TNM staging.56
In conclusion, this means that nodal involve-
ment seems to be of prognostic importance,
although the location in the mediastinum needs
to be interpreted differently from lung cancer.
Therefore, the N-descriptor was revised for the
eighth TNM classification to more MPM-specific
N-categories in comparison with the seventh edi-
tion, where the median survival for cN0 patients
was 19 months vs 17.6 and 16.2 months for cN1
and cN2 patients, respectively, without statistical
significance.55 Surgery alone for patients with pos-
itive ipsilateral mediastinal lymph nodes is not
appropriate, and a multimodality approach, partic-
ularly as part of a clinical trial, should be
considered.6
Selecting MPM patients for surgery based on
response to chemotherapy or other treatments
as a marker for biological behaviors is another op-
portunity. However, radiologic assessment of tu-
mor response to treatment using standard
RECIST (Response Evaluation Criteria in Solid Tu-
mors) criteria that require bidimensional measure-
ments is not practical and often difficult in
monitoring of mesothelioma,57 because the
morphology and growth pattern of mesothelioma
differs substantively from that of other solid tu-
mors.58 Based on restaging imaging by contrast-
enhanced CT or 18F-FDG PET/CT imaging after in-
duction chemotherapy and assessment of modi-
fied RECIST (mRECIST) criteria,59 patients are
classified as progressive disease, stable disease,
or partial response, and whether they are poten-
tially resectable or not. This method requires
acquisition of up to 6 measurements of tumor
thickness, each at least 1 cm in extent, perpendic-
ular to the chest wall or mediastinum59,60 with no
more than 2 measurement sites on each of 3 sepa-
rate CT sections separated axially by at least
1 cm,59 involving a multistage process with vari-
ability between observers at each of these steps.61
Consequently, this should be performed by a radi-
ologist familiar with mRECIST for MPM.62 Com-
plete or partial radiologic response is associated
with improved median survival of 26.0 vs
13.9 months for patients with stable disease or
progressive disease (P 5 .05).63 However, pro-
gressive disease alone is not an exclusion criterion
per se for surgery as long as MCR is still feasible
(Fig. 1 and Opitz and colleagues, unpublished
data).
For a more accurate evaluation of resectability in
terms of tumor load, tumor volume measured
before and after induction treatment is an attrac-
tive parameter. Conventional quantitative mea-
surement of the tumor volume (Fig. 2)47 and
newly deep convolutional neural network (CNN)-
automated volumetric segmentation of MPM tu-
mor on CT scans64 has been a field of interest
for prognostic evaluation of tumor staging65 and
response with reduction in tumor volume on CT66
or MRI67 after neoadjuvant treatment,47,68,69 as
well as prediction of survival.66 Furthermore,
already observed increasing tumor volume and
decreasing lung volume during neoadjuvant
chemotherapy are both significantly and indepen-
dently associated with poor prognosis.70
As described first in 1998 by Pass and col-
leagues,71 preoperatively assessed tumor volume
can predict OS and progression-free survival
(PFS) as well as postoperative stage. Large vol-
umes are associated with nodal spread as well
as postresection residual tumor burden and may
predict the outcome.47,65,71,72 In another study,
Gill and colleagues73 showed poorer OS if the tu-
mor volume was greater than 500 cm3, confirmed
by Rusch and colleagues,65 who reported that tu-
mor volumes of 91.2, 245.3, and 511.3 cm3 were
associated with a median OS of 37, 18, and
8 months, respectively.
Radiomic biomarkers had a stronger prognostic
value compared with tumor volume alone. The
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Fig. 1. Intention to treat (ITT) by response defined according to mRECIST criteria by independent observers (T.F.,
C.Z., D.-L.N.)59 in N5 218 patients before and after induction as was the tumor volume, which was assessed by the
help of semiautomated dedicated software as described previously.47 Partial regression does not seem more
beneficial compared with stable disease when considering survival times (HR, 0.9067194; CI, [0.6404001,
1.2837914]; P5 .58). However, a progressive disease response is associated with a significantly higher risk of dying
compared with a stable disease response (HR, 1.5496089; CI, [1.0230936, 2.347085]; P 5 .04).
Fig. 2. Volumetry of malignant
pleural mesothelioma. (A,B) The
marked tumor (green) on a single CT
slice.47
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authors evaluated radiomic features (shape, inten-
sity, texture [relation of an individual pixel to its
neighborhood], and wavelet decomposition), a
promising methodology for quantitative analysis
and description of radiologic images using
advanced mathematics and statistics in CT im-
ages, and a prognostic model for OS in MPM pa-
tients was developed based on these CT image
characteristics.74 Twowavelet features were prog-
nostic for OS in multivariable Cox regression
(concordance index: 0.74; P5 .002). Both features
separated the patients into 2 groups with a signif-
icantly different OS (P 5 .0006) and a significantly
different PFS (P 5 .003).69
MRI offers higher contrast resolution than CT
and is therefore potentially more appropriate for
volumetric analyses.75 Tumor volumes (300 mL)
had significantly poorer median OS (multivariable
Cox proportional hazards model, HR 2.114
[1.046–4.270], P5 .037).69 However, the observed
difference in median OS with tumor volume
increased when analysis was restricted to patients
with epithelioid histology and further increased
when epithelioid cases with nodal or metastatic
disease were excluded.69
Other functional imaging techniques using DWI
and DCE MRI have the potential to act as a quan-
titative method of assessing tumor response to
treatment.57 These techniques are reflective of
the underlying tumor pathophysiology, such as tis-
sue cellularity and microvessel density.57 In the
analysis of preoperative prediction of unresect-
ability in MPM, Burt and colleagues76 proposed a
novel metric of thoracic cage volume, calculated
by preoperative chest CT scan, and determined
associations between preoperative variables and
diffuse chest wall invasion (DCWI) and contraction
of thoracic cage volume in patients scheduled for
MCR. Decreased ipsilateral thoracic cage volume
demonstrated the strongest association with unre-
sectability by DCWI (P 5 .009), with greater than
5% decrease representing the optimal cutoff
(P 5 .014; area under the curve, 0.67). Preopera-
tive identification of DCWI can avoid unnecessary
thoracotomy and accelerate initiation of nonsur-
gical therapy.76 Other variables associated with
DCWI included chest pain requiring opioids
(P 5 .028), pleurodesis (P 5 .036), decreased
forced vital capacity (FVC) (P 5 .023), decreased
ipsilateral lung perfusion (P 5 .007), and chest
wall invasion (P 5 .035).76
Another potential selection tool for surgery or
supportive factor in the decision-making process
is the prognostic significance of maximum stan-
dardized uptake value (SUVmax) as assessed by
18F-FDG PET/CT, which measures tumor activity
and functional tumor volume to indicate patient
prognosis77 and is the focus of continued research
and clinical investigation.69 However, PET should
be interpreted with caution in patients after talc
pleurodesis.6 Recently, Lim and colleagues78 pro-
posed SUVmax as an independent prognostic fac-
tor in all patients (P 5 .003), especially those with
the epithelioid subtype associated with OS
(P 5 .012), but not in those with a nonepithelioid
subtype.
Finally, an important factor is the patients’ indi-
vidual expectation of postoperative quality of life
(QoL). Despite not unsubstantially reduced overall
QoL regarding ability to perform everyday activ-
ities that reflect physical, psychological, and social
well-being, and patient satisfaction with levels of
functioning and control of the disease after sur-
gery, some of these studies demonstrate a ten-
dency for better QoL (physical function, social
function, and global health were better at follow-
up) after lung-sparing surgery79 after 6 and
12 months,80 whereas other indicators such as
pain and cough were similar.79 This might be
related to the fact that with decortication of entrap-
ped lungs, lung function and, therefore, QoL can
improve. Predicted postoperative FEV1 (forced
expiratory volume in 1 s) and FVC were reported
in one study only and were higher at follow-up
for pleurectomy/decortication (P/D) compared
with extrapleural pneumonectomy (EPP).81
Pathologic Subtypes, and Genetic and
Molecular Factors
Benefit from surgery and survival for MPM is
significantly affected by tumor histology. The his-
tologic subtypes of MPM with epithelioid, sarco-
matoid, and biphasic type have clear prognostic
significance,6 which might help in selecting pa-
tients for intensive multimodal treatment ap-
proaches and in identifying whether patients are
eligible for surgery. The biphasic subtype showed
poor prognosis compared with the epithelioid sub-
type, whereas prognosis of the sarcomatoid sub-
type was worst in a recently published analysis
of the SEER database27 and consistent with previ-
ous studies and guidelines.6,8,10,29,52,53,82–84
Meyerhoff and colleagues24 reported that most
common epithelioid histology is related to better
survival compared with biphasic or sarcomatoid
histology (19 vs 12 vs 4 months in the sarcomatoid
group [P<.01]) and in multivariate analysis, surgery
was associated with improved survival in the
epithelioid group (HR 0.72, P<.01) but not in
biphasic (HR 0.73, P 5 .19) and sarcomatoid (HR
0.79, P5 .18) groups regardless of type of surgical
resection.
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According to the World Health Organization
2015 classification83,85 of epithelioid MPM, histo-
logic subtypes of predominantly microcystic/tubu-
lopapillary pattern were associated with longer OS
than the solid/trabecular subtype (732 vs
397 days, P 5 .0013), whereas the pleomorphic
subtype had the shortest OS (173 days).86 The
solid/trabecular variants showed a significant as-
sociation with a high nuclear grade and mitosis-
necrosis score as an independent prognostic fac-
tor.86 In a group of patients who received multi-
modal treatment, those with tubulopapillary/
microcystic pattern MPMs showed a tendency to-
ward better OS than those with solid/trabecular
pattern tumors (HR 2.29, 95% CI 0.95–5.12;
P 5 .066).86
Another current subject of further investigation
is grading, whereby well or moderately differenti-
ated subtypes resulted in better prognoses than
poorly differentiated or undifferentiated sub-
types,27 suggesting that nuclear atypia and mitotic
count are independent preoperative prognostic
markers for MPM.83
In conclusion, according to ASCO guidelines
surgery is not recommended in patients with sar-
comatoid MPM6; however, in carefully selected
cases biphasic or sarcomatoid subtype with nega-
tive mediastinal lymph node status is not obliged
to be excluded from surgery because this can be
the only option for these patients, given their
higher incidence of chemoresistance.52,87,88
Therefore, the decision for or against surgery
should not be based on a single factor such as his-
totype but rather a combination of various factors,
given that there are certain subtypes of epithelioid
MPM— biphasic or sarcomatoid histotypes—with
proven long-term survival.89,90
Genetic predisposition, as explored in preclini-
cal studies, is an important predictor of disease
progression and survival (discussed in detail in
Benjamin Wadowski and colleagues’ article, “The
Molecular Basis of Malignant Pleural
Mesothelioma,” in this issue). To date, it has not
been included in the decision-making process for
or against surgery. In brief, genetic prognostica-
tors include chromosome alterations of cyclin-
dependent kinase inhibitor 2A (CDKN2A) locus
(9p21.3), homozygous p16 deletions (especially
for sarcomatous type), and BRCA1-associated
protein 1 (BAP1) mutations, all of which are asso-
ciated with poor prognosis.91–93
In the following a few molecular prognostic fac-
tors, being a focus of the authors’ research area,
are briefly discussed, though not in depth because
this is the topic of Harvey I. Pass and colleagues’
article, “Mesothelioma Biomarkers: Discovery in
Search of Validation,” in this issue. However,
recommendations regarding the use of biomarkers
from current guidelines42 do not support bio-
markers in isolation as a diagnostic (Grade B) or
screening test (Grade C) or to predict treatment
response or survival (Grade B) in MPM.
MicroRNAs (miRNAs) are small noncoding RNA
molecules that regulate gene expression.94,95
Kirschner and colleagues96 established the miR-
Score, consisting of 6 miRNAs (miR-21-5p, -23-
3p, 30e-5p, 221-3p, -222-3p) for prediction of
longer survival in positive patients.
MPM is characterized by complex chromo-
somal aberrations, including chromosome 10 los-
ses and the tumor-suppressor gene phosphatase
and tensin homolog deleted from chromosome
10 (PTEN) located on chromosome 10q23. The au-
thors’ group showed that median survival time was
significantly longer in patients with PTEN expres-
sion (15.5 months: 95%CI 3.8, 27.2 vs 9.7 months:
95% CI 7.9, 11.7) independent of histologic sub-
type (P 5 .7).97,98 Furthermore, Schramm and col-
leagues99 demonstrated that low cytoplasmic
periostin and high cytoplasmic PTEN are indepen-
dent prognosticators of better OS.99 In addition,
the authors observed that a decrease in PTEN
and an increase in p-mTOR (pathologic mamma-
lian target of rapamycin) expression during induc-
tion chemotherapy were associated with shorter
OS.98 These investigations were recently
confirmed by Kuroda and colleagues,100 who
moreover proposed that molecular-targeted treat-
ment involving the mTOR signaling pathway might
be used during multimodal therapy for MPM.
Another prognosticator is cytokine migration
inhibitory factor (MIF) and its receptor CD74
together with calretinin in tissue microarray, which
correlates with OS. CD74 (P<.001) but not MIF
overexpression (P5 .231) is an independent prog-
nostic factor for prolonged OS.101 Interestingly
these positive results for CD74 were consistent
with a previously published report that high
expression of tumoral PTEN is an independent
prognostic factor for prolonged OS in mesotheli-
oma patients.97 High expression of tumor cell cal-
retinin correlated with the epithelioid histotype
predicted longer OS (P<.001).101 Thies and col-
leagues102 correlated the neural crest stem cell
marker nestin and the epithelial-mesenchymal
transition marker periostin with histology and
found that in platinum/pemetrexed-treated pa-
tients, nestin was higher in biphasic MPM
compared with epithelioid MPM, Regarding
expression of nestin in chemo-naı̈ve biopsies
(OS: 22 vs 17 months) and chemo-treated surgical
specimens (OS: 18 vs 12 months), both nonepithe-
lioid histology and high periostin level in biopsies
(OS: 23 vs 15 months) were associated with poor
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prognosis. In the multivariate survival analysis, any
nestin expression in chemo-naı̈ve biopsies proved
to be an independent prognosticator against his-
tology.102 Furthermore, Meerang and col-
leagues103 discovered that low Merlin expression
and high Survivin expression are also associated
with a poorer prognosis. These investigators
showed that cell proliferation marker Ki-67 and a
high nuclear Survivin-labeling index in prechemo-
therapy and postchemotherapy tissues were
associated with shorter freedom from recur-
rence.98,103 Programmed death-ligand 1 (PD-L1)
expression in tumor tissue was associated with a
lower median survival of 6 vs 15.5 months
compared with negative PD-L1, and positive PD-
L1 expression (1%) was independently corre-
lated with poor prognosis (HR 2.02, 95% CI,
1.005–4.057, P 5 .0484).104 Patients with PD-L1-
positive tumors had shorter OS than patients
with negative PD-L1 (HR 1.581, CI 1.043–2.396,
P 5 .031).36
In summary, although all of these markers
showed promising results, most have yet to be
independently and prospectively validated, and
for some of them controversial results from
different studies concerning their prognostic
impact need to be addressed.38 So far, all these
markers and their potential prognostic value have
had no impact on patient selection in predicting
outcome or monitoring tumor response,6 but may
be included in selection algorithms.
PROGNOSTIC SCORES
Because the use of a single factor to predict prog-
nosis is not justified, with rather the synthesis of
several factors leading to the decision for a cura-
tive operation, prognostic scores are of interest.
Combining groups of prognostic variables origi-
nating from cohorts of patients and subsequent
validation in different test cohorts42 seems to be
attractive for the identification of candidates for
surgery. The European Organization for Research
and Treatment of Cancer (EORTC) and the Cancer
and Leukemia Group B (CALGB) developed a
prognostic score and prognostic groups for better
identification of patients receiving different
chemotherapy regimens by analyzing the patients‘
pretreatment characteristics.10,11
The EORTC prognostic score10 includes the
ECOG PS, histologic subtype, gender, certainty
of diagnosis (definitive vs possible), and defined
good prognosis group (ECOG 0, epithelioid histol-
ogy, female, definitive diagnosis, and
WBC < 8.3  109/L) and poor prognosis group
(ECOG 1, nonepithelioid histology, male, possible
diagnosis, and WBC > 8.3  109/L). The CALGB
prognostic score is derived from 6 prognostic sub-
groups. Here poor ECOG PS, chest pain, dyspnea,
platelet count greater than 400 G/L, weight loss,
LDH level greater than 500 IU/L, pleural involve-
ment, low Hb level, high WBC count, and age
greater than 75 years predicted poor survival.
Pleural involvement, LDH greater than 500 IU/L,
poor PS, chest pain, PLT greater than 400,000/
mL, nonepithelial histology, and age greater than
75 years predicted poor survival in multivariate
analysis.11 The subgroup with the best survival
included patients with PS 0 and age less than
49 years, and patients with PS 0, age 49 years or
older, and hemoglobin S14.6 g/L. The worst sur-
vival occurred for patients with PS 1/2 and WBC
S15.6/mL.11
Edwards and colleagues12 validated the effec-
tiveness of the EORTC and CALGB scores as early
as 20 years ago. Patients were stratified into low-
risk and high-risk groups and correlated with the
EORTC series with a median survival of 9.4 vs
10.8months (low-risk group) and 3.8 vs 5.5months
(high-risk group), respectively.12. The EORTC
score was recently evaluated by the Italian group
of Sandri.105 Multivariable analysis confirmed an
independent prognostic value of EORTC score
(HR 2.86, P<.001) as a reliable and valid instrument
that may be implemented in daily practice.105
Furthermore, an Italian group explored predic-
tors of long-term survival and defined a prognostic
score in a multicenter analysis.106 On multivariate
analysis, younger age (OR 0.51, 95% CI 0.31–
0.82), epithelioid histology (OR 7.07, 95% CI
1.56–31.93), no history of asbestos exposure (OR
3.13, 95% CI 1.13–8.66), and the ratio between
metastatic and resected lymph nodes less than
22% (OR 4.12, 95% CI 1.68–10.12) were indepen-
dent predictors of long-term survival. Long-term
survival was defined as survival longer than 2
times the median OS (18months) and stratified pa-
tients into 2 groups: 36 months (long-term survival
group) and those surviving between 4 and
35 months (short-term survival group). The investi-
gators created a scoring system (1–12 points)
identifying patients for long-term survival with a
score greater than 6 and predicting favorable over-
all, cancer-specific, and disease-free survival
(P<.0001).106
Pass, Rusch, and colleagues107,108 identified
prognostically important and independent covari-
ates for prediction of survival including stage,
age, gender, histology (epithelioid vs nonepithe-
lioid), and the type of surgical procedure (palliative
vs curative), defined as “CORE” values, and
analyzed their impact on OS: adjuvant therapy
(yes: OS 18 months vs no: OS 10 months), smok-
ing history (no: OS 16 months vs yes: OS
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15 months), history of asbestos exposure (no: OS
17 months vs yes: OS 15 months), history of
weight loss, defined as greater than 5% (OS
11 months) vs less than 5% (OS 17 months) in
the previous 6months, ECOGPS 0 (OS 22months)
and 1 (OS 16 months), chest pain (no: OS
19 months vs yes: OS 14 months); and dyspnea
(no: OS 15 months vs yes: OS 17 months), Hb level
(<14.6; OS 16 months vs >14.6 OS 20 months),
platelet count (<400; OS 19 months vs >400 OS
12 months), WBC count (<15.5; OS 16 months
vs >15.5 OS 8 months), and LDH level before sur-
gery. In total, they defined 3 prognostic models
with these covariates. Models 1 and 2 included
the CORE variables. Model 1 additionally included
adjuvant treatment, WBC, and platelet count, and
model 2 consisted of the same covariates as
model 1 but without a surgical staging, with Hb
added as additional parameter. Model 3 showed
only parameters available before surgery (histol-
ogy, gender, age, WBC, Hb, and platelets) and
therefore represented the potential surgery pa-
tient. The models per se were not analyzed ac-
cording to their prognostic value; only their
covariates were individually indicated as having
prognostic significance and HR.107,108
The modified Glasgow Prognostic Score
(mGPS) categorizes patients with cancer accord-
ing to CRP and serum albumin.15 This was found
to be an independent predictor of OS in MPM
(HR 2.6, 95% CI 1.6–4.2, P<.001)15 and has not
been further prospectively validated. Both mGPS
and NLR were independent predictors of OS (HR
2.6 and 2.0, respectively).15
The LENT prognostic score was developed by
Clive and colleagues109 for predicting survival in
patients presenting with malignant pleural effusion
using LDH (>1500) IU/L, ECOG PS, NLR, and tu-
mor type. Analysis of the area under the receiver-
operating characteristic (ROC) curve revealed the
LENT score to be superior at predicting survival
compared with ECOG PS at 1 month (P<.01),
3 months (P<.01), and 6 months (P<.01).109
Another prognostic score using decision tree
analysis was published by Brims and col-
leagues110 who developed and validated a sim-
ple, clinically relevant model to discriminate
patients at high and lower risk of death using
routinely available variables from the time of
diagnosis. The strongest predictive variable was
the presence of weight loss. The group with the
best survival at 18 months (86.7% alive, median
survival 34.0 months, termed risk group 1) had
no weight loss, an Hb level of >153 g/L, and a
serum albumin level of >43 g/L. The group with
the worst survival (0% alive, median survival
7.5 months, termed risk group 4d) had weight
loss, a PS of 0 or 1, and sarcomatoid histologic
characteristics.110
A Japanese group led by Doi111 developed a
new Novel Prognostic Risk Classification Sys-
tem.111 Pathologic subtype, serum LDH, NLR ra-
tio, and total lesion glycolysis (TLG) in 18F-FDG
PET/CT were independent and significant prog-
nostic factors. Univariate and multivariate ana-
lyses revealed that the significant independent
predictors of poor survival outcomes were the
nonepithelioid histologic type, increased serum
LDH, an NLR of 5.0, and a TLG of 525 g.111
Fig. 3. MMP Score. Kaplan-Meier
curve comparing overall survival (OS)
according to the multimodality prog-
nostic score (MMPS score) in patients
treated with induction chemotherapy
followed by MCR. Source: Opitz et al.
2015 unpublished data.
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The problem with most of the scores so far is the
lack of validation in independent cohorts and the
inclusion of clinical variables being available
before surgery to help decision-making for or
against surgical resection.112 For this purpose,
the authors defined in 2012 a multimodality prog-
nostic score (MMPS) to screen patients and define
subgroups eligible or especially not eligible for sur-
gery.113 The items in the score consisted of tumor
volume before chemotherapy (>500 mL), nonepi-
thelioid histologic subtype, CRP greater than
30 mg/L before chemotherapy, and progressive
disease after chemotherapy assessed by mRE-
CIST criteria. The cutoff within this score was at
2 and the specificity of scores 3 and 4 was
100%. The median OS for patients with a score
of 0, 1, and 2 was 34, 17, and 12 months, respec-
tively, whereas patients with a score of 3 or 4 had a
median OS of 4 months (Fig. 3). The knowledge
gained from the MMPS is important for counseling
patients because it allows one to reliably identify
patients who may have a good chance to benefit
from multimodality therapy including surgery and
to rule out those in whom aggressive treatment
may even cause harm. With a score of 3 or higher,
patients are not considered to profit from an MCR
in a multimodality therapy approach.113 This score
was further validated in an independent cohort
from Vienna (Fig. 4) treated with the identical multi-
modality concept,113 so that currently the authors
are prospectively evaluating the score as an inclu-
sion criterion for clinical trials.112 The comparison
of MMPS score with EORTC score using ROC
curve analysis at 2 years showed that the MMPS
demonstrated a better predictive power for OS
than the EORTC score.10,113
The recommendations from current BTS guide-
lines for the investigation and management of
MPM42 include the following (all grade D).
Consider calculating a prognostic score in patients
Fig. 4. Kaplan-Meier curve of overall survival (OS) in months of the multimodality prognostic score. (A) Patients
treated with induction chemotherapy followed by extrapleural pneumonectomy (EPP; Zurich). (B) Patients of the
intention-to-treat group (Zurich). (C) Patients treated with induction chemotherapy followed by EPP (Vienna).
(From Opitz I, Friess M, Kestenholz P, et al. A new prognostic score supporting treatment allocation for multimo-
dality therapy for malignant pleural mesothelioma: a review of 12 years’ experience. J Thorac Oncol.
2015;10(11):1640; with permission.)
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with MPM at diagnosis. Prognostic scores can
provide useful survival information for patients
and doctors but should not be used in treatment
decision-making. When calculating a prognostic
score, use one of the following: (a) the EORTC
PS; (b) the CALGB score; (c) the mGPS; (d) the
LENT score if a pleural effusion is present; (e) the
decision tree analysis. The decision tree analysis
scoring system is likely to be the most useful in
routine clinical practice.42 Future investigations
needs to extend staging supplemental variables
with validation of already available clinical prog-
nostic indices (EORTC and CALGB scores) in
combination with laboratory parameters or bio-
markers to define the best surgical candidates,
as recommended in the ASCO guidelines.6
SUMMARY
Currently there are no generally accepted criteria
for patient selection for surgery within a multimo-
dality treatment protocol, but patient selection re-
mains the key parameter for surgical success and
low morbidity and mortality. Among clinical, path-
ologic, and molecular prognostic factors studied in
the past, the combination of several factors seems
to be the most appropriate tool for decision-
making, including also institutional experience
and availability of therapy as well as factors such
as the patient’s choice of treatment. Preoperative
identification of benefit from surgery comprising
a summary of interdisciplinary preoperative
workup includes many aspects in this decision-
making process, including exact diagnosis, stag-
ing, validated prognostic scores, multimodal ther-
apy options based on recommendations of the
multidisciplinary tumor board, and prospective
evaluation of these treatment allocation protocols,
when selecting the appropriate therapy for pa-
tients in the future. In appropriately selected pa-
tients with an acceptable risk profile, surgical
resection (extended P/D, P/D, or EPP) as part of
a multimodality concept should still be offered if
performed in high-volume and low-mortality cen-
ters, and in any case inclusion in clinical trials or
large national or international registries is
recommended.
Clinics Care Points
 Preoperative identification of benefit from sur-
gery is contributed by clinical prognosticators
(including age, gender, ECOG PS status,
radiologic and surgical staging at baseline
and after induction treatment, genetic and
molecular factors, laboratory parameters)
which, combined with consideration of QoL,
are applied often in prognostic scores and
allow identification of selected patients for
curative approach.
 Future prospective randomized trials must
validate all of these approaches to select the
best surgical candidates according to
approved international guidelines.
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